Single Molecule Real Time (SMRT®) sequencing products, today
announced the appointment of
Chairman of its Board of Directors. Dr. Hunkapiller, a
at
member of the PacBio Board since 2005.
President and Chief Executive Officer.
“Mike has been a driving force in the sequencing industry for three
decades, and we are honored that he has agreed to take a more active
role with PacBio,” said
draw more heavily on his expertise, experience and relationships with
customers in the life science tools market.”
Dr. Hunkapiller commented: “I have spent much of my career on the
leading edge of sequencing technology and I believe PacBio’s single
molecule, real-time technology will disrupt the sequencing market. I am
delighted that Hugh and the Board asked me to take on this newly created
role and look forward to devoting more time to advising the company on
how to accelerate adoption of their products in important applications.”
A renowned scientist, entrepreneur and life science industry executive,
Dr. Hunkapiller spent 21 years at Applied Biosystems (ABI), which he
co-founded and helped grow from startup to nearly
revenues supplying instrument and reagent systems for life science
research. He was also a founder of ABI’s sister company Celera Genomics
and Senior Vice President of
to joining ABI, Mike was a senior research fellow in the
Biology at the
For more information about Pacific Biosciences, please visit www.pacificbiosciences.com.
You can also follow the company on twitter www.twitter.com/pacbio.
About Pacific Biosciences
Pacific Biosciences’ mission is to transform the way humankind acquires,
processes and interprets data from living systems through the design,
development and commercialization of innovative tools for biological
research. The company has developed a novel approach to studying the
synthesis and regulation of DNA, RNA and proteins. Combining recent
advances in nanofabrication, biochemistry, molecular biology, surface
chemistry and optics, Pacific Biosciences has created a powerful
technology platform called single molecule, real-time, or SMRT®,
technology. SMRT technology enables real-time analysis of biomolecules
with single molecule resolution, which has the potential to transform
the understanding of biological systems by providing a window into these
systems that has not previously been open for scientific study.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking
statements may contain words such as “believe,” “may,” “estimate,”
“anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of
these terms, or other similar expressions, and include the assumptions
that underlie such statements. Such statements include, but are not
limited to, statements regarding the Company’s SMRT technology. These
statements are subject to known and unknown risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements, including but not limited to risks discussed
from time to time in documents
has filed with the
risks identified under the section captioned “Risk Factors” in its
recently filed Quarterly Report on Form 10-Q. All forward-looking
statements are based on estimates, projections and assumptions as of the
date hereof. Pacific Biosciences undertakes no obligation to update any
forward-looking statements.
Photos/Multimedia Gallery Available: https://www.businesswire.com/cgi-bin/mmg.cgi?eid=50045971&lang=en
For Pacific Biosciences
nicole@bioscribe.com
or
Pacific
Biosciences
ir@pacificbiosciences.com
Source:
News Provided by Acquire Media